Stimulating research
A joint US and Japanese research team has taken the hope for successful treatments of neurodegenerative diseases a step further...
A joint US and Japanese research team has taken the hope for successful treatments of neurodegenerative diseases a step further. The group has discovered a novel way to stimulate nerve cells to release protective antioxidants (the body's natural defenses against oxidative stress caused by free radicals). Oxidative stress is thought to be aetiologically important in many neurodegenerative diseases such as Alzheimer's and Lou Gehrig's diseases. The causes are not fully understood though accumulation of glutamate - an excitatory neurotransmitter - may be responsible.
The pathway for protection is thought to involve neurite outgrowth-promoting prostaglandins activating the Keap1/Nrf2 pathway, which is responsible for antioxidant production. The research could lead to a new drug treatment for diseases such as Alzheimer's. Currently there are estimated to be 24.3 million dementia sufferers worldwide, a figure predicted to rise to 81.1 million by 2040. The increasing prevalence of dementia is linked to the ageing global population, and has serious repercussions from personal up to governmental levels.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
